Education
About Us
Working with TipRanks
Follow Us
MedinCell SA (FR:MEDCL)
:MEDCL
MEDCL Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MEDCL Stock 12 Month Forecast
Average Price Target
€28.80
▲(11.80% Upside)
| Highest Price Target€32.00 | Average Price Target€28.80 | Lowest Price Target€25.60 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
€32
Buy
24.22%
Upside
Reiterated
09/29/25
MedinCell SA: Promising Growth in Long-Acting Injectable Market with Strategic Collaborations and Expanding Product PortfolioValuation and Risks. We assess MedinCell's prospects using a discounted cash flow (DCF)-based valuation methodology. Applying an 11% discount rate and 1% terminal rate of decline along with an 85% probability of approval for mdc-TJK and a 40% probability of approval for mdc-CWM, we derive a total firm value of roughly $1.24B and a price objective of €32 per share based on an exchange rate of $1.17 per €1. Risks include, but are not limited to: (1) inability to submit a regulatory application for approval of mdc-TJK in the U.S.
Kepler Capital
€25.6
Buy
-0.62%
Downside
Reiterated
09/23/25
Truist Financial
€22
Buy
-14.60%
Downside
Initiated
05/27/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
€32
Buy
24.22%
Upside
Reiterated
09/29/25
MedinCell SA: Promising Growth in Long-Acting Injectable Market with Strategic Collaborations and Expanding Product PortfolioValuation and Risks. We assess MedinCell's prospects using a discounted cash flow (DCF)-based valuation methodology. Applying an 11% discount rate and 1% terminal rate of decline along with an 85% probability of approval for mdc-TJK and a 40% probability of approval for mdc-CWM, we derive a total firm value of roughly $1.24B and a price objective of €32 per share based on an exchange rate of $1.17 per €1. Risks include, but are not limited to: (1) inability to submit a regulatory application for approval of mdc-TJK in the U.S.
Kepler Capital
€25.6
Buy
-0.62%
Downside
Reiterated
09/23/25
Truist Financial
€22
Buy
-14.60%
Downside
Initiated
05/27/25
Best Analysts Covering MedinCell SA
1 Month
xxx
Success Rate
12/17 ratings generated profit
Average Return
+3.87%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 70.59% of your transactions generating a profit, with an average return of +3.87% per trade.
3 Months
xxx
Success Rate
10/17 ratings generated profit
Average Return
+9.75%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 58.82% of your transactions generating a profit, with an average return of +9.75% per trade.
1 Year
Success Rate
15/17 ratings generated profit
Average Return
+59.95%
reiterated a buy rating 12 days ago
Copying Nicolas Pauillac's trades and holding each position for 1 Year would result in 88.24% of your transactions generating a profit, with an average return of +59.95% per trade.
2 Years
xxx
Success Rate
17/17 ratings generated profit
Average Return
+104.27%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +104.27% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MEDCL Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Aug 25
Sep 25
Strong Buy
4
3
2
1
1
Buy
4
4
2
2
3
Hold
0
0
0
1
1
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
9
8
5
4
5
Each month's total comprises the sum of three months' worth of ratings.
MEDCL Financial Forecast
MEDCL Stock Forecast FAQ
What is FR:MEDCL’s average 12-month price target, according to analysts?
Based on analyst ratings, MedinCell SA’s 12-month average price target is 28.80.
What is FR:MEDCL’s upside potential, based on the analysts’ average price target?
MedinCell SA has 11.80% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MedinCell SA a Buy, Sell or Hold?
MedinCell SA has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is MedinCell SA’s share price target?
The average share price target for MedinCell SA is 28.80. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €32.00 ,and the lowest forecast is €25.60. The average share price target represents 11.80% Increase from the current price of €25.76.
The highest analyst share price target is €32.00 ,and the lowest forecast is €25.60. The average share price target represents 11.80% Increase from the current price of €25.76.
What do analysts say about MedinCell SA?
MedinCell SA’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of MedinCell SA?
To buy shares of FR:MEDCL, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.